Crispr Therapeutics shares tumble after significant earnings miss
LONDON - The abrdn UK Smaller Companies Growth Trust PLC has announced the approval of two key resolutions following a General Meeting held on May 21, 2025. Shareholders voted in favor of both the cancellation of the share premium account and the authorization for the company to make market purchases of its own ordinary shares.
The first resolution, which passed with 99.83% of votes, involves the cancellation of the amount standing to the credit of the share premium account of the company. The resulting amount from the reduction of share capital will be credited to a reserve within the company. A total of 20,306,556 votes were cast on this resolution, with 15,362 votes withheld.
The second resolution, which allows the company to repurchase its own shares, received 94.02% approval from shareholders. The limit on the number of ordinary shares available for buyback is set at 9,508,781 as of the date of the meeting. This resolution saw a total of 20,311,935 votes, with 9,983 withheld.
The full text of the resolutions is available in the Circular to Shareholders dated April 24, 2025, which can be found on the company’s website. The Circular has also been submitted to the National Storage Mechanism and is available for inspection.
The approval of these resolutions by the shareholders is a significant step for the abrdn UK Smaller Companies Growth Trust PLC, as it gives the company more flexibility in managing its capital structure and the ability to return value to shareholders through the repurchase of shares. This information is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.